We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

ccfDNA Workflows: Honing In On the Target

Doug Horejsh leads a nucleic acid purification research group at Promega.  Prior to joining Promega, Doug held clinical director and senior research roles at AI Biotech, Commonwealth Biotechnologies, and the Italian National Institute for Infectious Diseases.  He received his Ph.D. from the Cell and Molecular Biology Program at the University of Wisconsin-Madison.
  • Douglas Horejsh, Ph.D.

  • Senior Research Scientist
    Promega Corporation

Tuesday, August 13, 2019

ccfDNA Webinar Series: The Basics and Beyond

Circulating cell-free DNA (ccfDNA) is a key area of interest in the study of normal and disease states.

In Part 2 of 3 ccfDNA Webinars, we will discuss key considerations and methodologies for isolating ccfDNA, including:

  • Optimized purification of ccfDNA
  • Methods for ccfDNA QC and detection of genomic DNA contamination
  • Tips and tricks for removing gDNA contamination to ensure targeted sequencing of your desired ccfDNA

 

Register for the other parts in this series:

Part 1 - ccfDNA 101: Emerging Trends in Oncology Research

Part 3 - ccfDNA In the Lab: Optimizing Purification for Sequencing 

Additional Webinar Information:

Circulating cell-free DNA (ccfDNA) is one of the most promising sources of DNA-based information for oncology research available today. Scientists continue to look for better ways to actively target the precious small fragment DNA necessary for liquid biopsy applications.

The low concentration and highly fragmented nature of ccfDNA, coupled with the low frequency of biomarkers of interest, present many challenges to the adoption of ccfDNA monitoring. In this webinar, we will discuss techniques for maximizing results through proper sample handling, purification, quantitation, QC, and downstream processing of ccfDNA.